These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8735552)

  • 1. Suppression of virus burden by immunization with feline immunodeficiency virus Env protein.
    Hosie MJ; Dunsford TH; de Ronde A; Willett BJ; Cannon CA; Neil JC; Jarrett O
    Vaccine; 1996 Apr; 14(5):405-11. PubMed ID: 8735552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
    Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
    Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.
    Hosie MJ; Flynn JN
    J Virol; 1996 Nov; 70(11):7561-8. PubMed ID: 8892875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus.
    Cuisinier AM; Mallet V; Meyer A; Caldora C; Aubert A
    Vaccine; 1997 Jul; 15(10):1085-94. PubMed ID: 9269051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus.
    Gonin P; Fournier A; Oualikene W; Moraillon A; Eloit M
    Vet Microbiol; 1995 Aug; 45(4):393-401. PubMed ID: 7483252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
    Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
    Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.
    Lombardi S; Garzelli C; Pistello M; Massi C; Matteucci D; Baldinotti F; Cammarota G; da Prato L; Bandecchi P; Tozzini F
    J Virol; 1994 Dec; 68(12):8374-9. PubMed ID: 7966629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.
    Siebelink KH; Tijhaar E; Huisman RC; Huisman W; de Ronde A; Darby IH; Francis MJ; Rimmelzwaan GF; Osterhaus AD
    J Virol; 1995 Jun; 69(6):3704-11. PubMed ID: 7745719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
    Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
    Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
    Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
    J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of subunit vaccines against feline immunodeficiency virus infection.
    Verschoor EJ; Willemse MJ; Stam JG; van Vliet AL; Pouwels H; Chalmers SK; Horzinek MC; Sondermeijer PJ; Hesselink W; de Ronde A
    Vaccine; 1996 Mar; 14(4):285-9. PubMed ID: 8744554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus.
    Matteucci D; Pistello M; Mazzetti P; Giannecchini S; Isola P; Merico A; Zaccaro L; Rizzuti A; Bendinelli M
    Vaccine; 1999 Aug; 18(1-2):119-30. PubMed ID: 10501242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.
    Mazzetti P; Giannecchini S; Del Mauro D; Matteucci D; Portincasa P; Merico A; Chezzi C; Bendinelli M
    J Virol; 1999 Jan; 73(1):1-10. PubMed ID: 9847300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.
    Hosie MJ; Klein D; Binley JM; Dunsford TH; Jarrett O; Neil JC; Knapp E; Giannecchini S; Matteucci D; Bendinelli M; Hoxie JA; Willett BJ
    J Virol; 2005 Feb; 79(3):1954-7. PubMed ID: 15650222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.
    Richardson J; Moraillon A; Baud S; Cuisinier AM; Sonigo P; Pancino G
    J Virol; 1997 Dec; 71(12):9640-9. PubMed ID: 9371628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
    Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection.
    Cuisinier AM; Meyer A; Chatrenet B; Verdier AS; Aubert A
    Vaccine; 1999 Feb; 17(5):415-25. PubMed ID: 10073718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.